Current News

Contact | Print version | PDF version | Send article | RSS feed

SR Pharma plc Announces Therapeutic Efficacy of Atu027 RNAi in pre-clinical Models of Pancreatic Cancer

01 Dec 2006 - SR Pharma plc announced that studies at the Charité Hospital have demonstrated the superior therapeutic efficacy of Atu027 RNAi in pre-clinical models of pancreatic cancer when compared to the standard care treatment. The data showed both inhibition of cancer growth and prevention of metastatic spread, demonstrating potent efficacy and effective systemic delivery with no adverse events. According to the compnay, Atu027 RNAi was significantly more effective in the prevention of metastases than Gemcitabine®. The novel anti-angiogenic treatment was feasible, safe and effective in vivo. The growth inhibitory and anti-metastatic effects of Atu027 RNAi in the clinically relevant in vivo model fully support further development of this substance for pancreatic cancer. A phase I clinical trial using Atu027 RNAi in patients suffering from pancreatic cancer is scheduled to start in 2007.